RESEARKA

This synthesis tests the thesis that evidence for Aerobic exercise is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation.

Aerobic exercise is widely promoted for healthy aging, yet the evidence linking it to cardiometabolic and functional outcomes in older adults remains heterogeneous, raising the question of whether mechanistic plausibility translates into consistent clinical benefit.

This synthesis applied a structured, AI-assisted evidence appraisal to 129 curated reference papers spanning observational cohorts, systematic reviews, and meta-analyses, with each claim anchored to sources and effect-direction coding.

In advanced atherosclerotic Apoe-/- mouse models, does ABT-263 senolytic treatment support a narrow warning that senescent-cell clearance can reduce smooth-muscle-associated plaque features while simultaneously increasing endothelial-to-mesenchymal transition and mortality risk, and should this signal be framed as a therapeutic-window concern rather than as evidence that senolytics are broadly harmful or broadly beneficial?

This submission uses the retained Researka v4 senolytic evidence run from 2026-05-17. The load-bearing receipts are three A-core numeric facts from the same 2024 JCI Insight source on advanced atherosclerotic Apoe-/- mice treated with ABT-263. Additional source-bundle entries provide contextual senolytic receipts from the same run so reviewers can see the broader topic boundary, but they are not used to broaden the main claim.

The central evidence is source-concentrated and preclinical. That is acceptable only for a frontier warning memo because the signal is counter-consensus and internally coherent: the same model/source reports plaque-cell reduction, EndoMT increase, and mortality risk. Contextual bundle papers cover adjacent senolytic biology, but the thesis should remain limited to advanced plaque biology and ABT-263 rather than general anti-aging use.

Source scope:** 16 A/B-bound receipts across 10 evidence sources; 12 total references in the source bundle. Two source-bundle entries are corpus-context references for breadth, not thesis proof; schema labels still use primary/review only.

The exercise corpus in this run supports a broader alpha signal: exercise effects are endpoint- and context-specific rather than uniformly generalizable. The strongest bound receipts span inflammatory markers, exercise capacity and mortality, tumor-model response, angiogenesis biomarkers, muscle-protein synthesis, peripheral oxygen extraction, dietary inflammatory index, and NO/exercise muscle effects.

The common story treats exercise as a single beneficial geroscience intervention. This evidence map says the more useful signal is specificity: different populations, endpoints, and mechanisms move differently, so the publishable claim is not “exercise works,” but “exercise signals need endpoint- and context-specific interpretation.”

Telomere length emerges as a dualistic biomarker where elongation simultaneously lowers cardiovascular risk but elevates cancer susceptibility, with the magnitude of these effects critically modulated by genetic variants, measurement precision, and disease-specific contexts like pulmonary fibrosis.

Known / obvious (do not republish): Telomere length shortens with age; Shorter telomeres are generally associated with higher mortality risk; Telomere length is influenced by genetic factors

Real tension: Fact 1 shows genetically determined longer telomere length lowers coronary heart disease risk, while facts 4 and 7 indicate it raises cancer risk, creating a therapeutic dilemma.

What does the current evidence establish about Caloric Restriction and human geroscience? This synthesis tests the thesis that evidence for Caloric restriction is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Caloric restriction (CR) is the most robustly replicated lifespan-extending intervention in animal models, yet its translational value for human aging and cardiometabolic health remains a central debate in geroscience. This synthesis applies a structured, audit-traced evidence approach to systematically appraise the published literature, prioritizing mechanistic plausibility against functional outcomes from human trials and large observational cohorts. Synthesis of 171 curated studies reveals that CR consistently improves cardiometabolic markers, with mean arterial pressure (P < 0.05) and lipid-related risk factors (P < 0.05) significantly decreasing after 12 weeks of intervention (Abdollahpour 2025, Huffman 2022). Anthropometric benefits are robustly demonstrated, as CR in women with obesity (Pescari 2024) and postmenopausal cohorts (Seimon 2019) significantly reduced body weight and fat mass (P < 0.001), though a significant proportion of weight loss is attributed to lean mass reduction. The tension between mechanistic longevity benefits and clinical functional trade-offs is stark: CR induced positive cardiometabolic shifts (Yi 2025) yet failed to maintain bone mi

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating.

Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.

The direct receipts support a narrow working claim: Compared with control, exercise alone reduced hs-CRP [-30.2%; 95% CI, -50.3, -1.0]; exercise alone reduced hs-CRP and IL6 (-30.9%; 95% CI, -47.3, -9.5). The context receipts provide source breadth and boundary checks, not independent confirmation of the lead claim.

The useful signal is narrower than the topic label: the lead receipts support the core claim, while the added A/B context receipts define where that claim may generalize, fail, or need a separate extraction.

`fact_id=12572` (`A_core`) — Mixed-muscle protein fractional synthetic rate increased by 42% at 3 h postexercise and 69% at 24 h postexercise in CON. DOI `10.1152/ajpendo.00600.2013`

What does the current evidence establish about Rapamycin and human geroscience? Rapamycin, an mTOR pathway inhibitor, has emerged as a leading candidate geroprotective agent, yet translating its robust preclinical lifespan benefits to humans requires reconciling mechanistic promise with functional and safety trade-offs. We conducted a structured evidence synthesis across curated preclinical, clinical, and observational sources, applying transparent inclusion criteria and an audit trail to adjudicate tensions between mechanistic plausibility and clinical signal. Pharmacokinetic analyses of real-world low-dose cohorts reveal considerable inter-individual variability in trough blood rapamycin levels, with compounded formulations showing different bioavailability profiles than commercial generics (P < 0.001 for formulation comparisons; Harinath 2025), a finding that complicates dose standardization across aging-relevant trials. On the mechanistic side, additive geroprotection has been demonstrated when rapamycin is combined with trametinib (Gkioni 2025, multiple endpoints at P < 0.05), and even two weeks of treatment increased ovarian lifespan in young and middle-aged female mice (Dou 2017, P < 0.05), while rapamycin reversed age-related vascular dysfunction in old B6D2F1 mice (P < 0.05 across endpoints; Lesniewski 2016). The weight of evidence supports rapamycin's mechanistic plausibility as a geroprotector—autophagy induction, senescence suppression, and imm

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating.